Polymer nano-systems for the encapsulation and delivery of active biomacromolecular therapeutic agents

Abstract

The ability of biomacromolecular therapeutic agents to treat various diseases is limited by the challenges faced in their delivery. Here we review how the design of polymer-based nanosystems can provide modular solutions to face those delivery issues.

New diagnostic and therapeutic strategies for myocardial infarction via nanomaterials

“…Compared to liposomes, polyelectrolyte complex, such as poly-lysine, showed increased nucleic acid-retention time through hydrophobic forces, electrostatic, and hydrogen bonding. 142 The ratio of DNA/poly-lysine mass concentration between two to three has been proved to carry the highest DNA. 143 Yet, there were few studies focusing on the optimal concentration ratio to carry miRNA.…”

Self-adjuvanting cancer nanovaccines

“…(2) The use of nanoparticles often offers better spatial and temporal delivery of vaccines [ 20 ]. Vaccine accumulation in LN can be significantly enhanced by manipulating the size, charge and other physical and chemical features of nanoparticles [ 21 , 22 ]. Compared with free antigen, nanoparticles with sizes between 20 and 100 nm can be absorbed and retained within lymphatics [ 23 ].…”

Passerini chemistries for synthesis of polymer pro-drug and polymersome drug delivery nanoparticles

“…3,4 In addition, for systemic administration, it is advantageous if the polymers can assemble into nanoscale particles with a hydrophilic exterior, in order to circulate in the bloodstream and avoid early excretion. [5][6][7] However, most existing polymer drug delivery systems in the clinic are derived from a relatively small range of lactides, glycolides and lactones. 8 These chemistries are sub-optimal in terms of the ultimate function of biomedical polymer structures, with problems of poor compatibility with candidate drug compounds and low functional group content without complex and costly synthesis.…”